Moleculin Biotech (NASDAQ:MBRX) Announces Earnings Results, Beats Estimates By $0.07 EPS

Moleculin Biotech (NASDAQ:MBRX) announced its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.07, Zacks reports.

Moleculin Biotech Stock Performance

Shares of Moleculin Biotech stock traded down $0.02 during trading hours on Friday, reaching $0.43. 1,285,246 shares of the company were exchanged, compared to its average volume of 5,271,311. The firm has a market cap of $21.47 million, a PE ratio of -0.13 and a beta of 1.57. Moleculin Biotech has a 1 year low of $0.25 and a 1 year high of $3.65. The stock’s fifty day moving average is $0.46 and its 200 day moving average is $0.60.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Wall Street Zen lowered Moleculin Biotech to a “strong sell” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Moleculin Biotech in a research report on Wednesday, September 10th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.